Good stacking is not "more peptides." It is adding the missing piece after the main compound has already defined the problem.
A stack should answer one clean question:
What is the bottleneck the current protocol does not solve?
For a GLP-1 user, the bottleneck might be fatigue, lean-mass loss, appetite rebound, or a true plateau. For an injury user, it might be blood flow, repair-cell movement, inflammation, collagen quality, pain, or sleep. For a skin protocol, it might be collagen signaling, redness, hair shedding, or caloric-deficit stress.
If the bottleneck is not clear, the stack is not ready.
At a Glance
| Rule | Practical Meaning |
|---|---|
| Anchor first | The compound that fits the main goal carries the protocol. |
| Add one layer | One missing support layer at a time, not a whole menu. |
| Do not stack through | Active side effects, under-eating, dehydration, poor sleep, or unclear reactions. |
| Keep signals readable | One new compound at a time keeps benefits and side effects traceable. |
| Let protocol pages own dosing | This guide routes the stack; dedicated pages handle dose and cadence. |
When Not to Stack
The most useful stacking answer is sometimes "not yet."
A working anchor blocks the next peptide. When tirzepatide, BPC-157, GLOW, NAD+, or ipamorelin is producing the goal with tolerable side effects, a held protocol lets the signal mature; a second variable only muddies it.
Active side effects block a cover-up peptide. Nausea, constipation, appetite collapse, elevated resting heart rate, insomnia, fatigue, edema, welts, flushing, or training collapse mark an unstable baseline. A compound layered on top hides the cause rather than resolving it.
Unprotected basics block the whole stack. Protein, hydration, electrolytes, resistance training, sleep, bowel function, and injection technique are not optional background details. Many "peptide failures" are really support failures.
A route problem is not a stack problem. When NAD+ burns, MOTS-c welts, or GHK-Cu stings, the fix is route, dilution, injection depth, speed, or BAC-water choice — not a protocol change.
The Stack Router
This is the first-pass map. The linked protocol pages carry exact dosing, timing, and cycle length.
Weight loss / food noise
Anchor: tirzepatide for most users; semaglutide where GLP-1-only simplicity, access, outcomes evidence, or prior tolerability matters.
Layer when: fatigue, lean-mass loss, plateau, or post-stop planning appears.
Full guide: Semaglutide vs Tirzepatide
Retatrutide / advanced GLP-1 use
Anchor: low-and-slow retatrutide, especially for visceral-fat, liver-fat, plateau, or recomp phenotype.
Layer when: NAD+, lean-mass support, or transition logic is the missing piece.
Full guide: Retatrutide Guide
GLP-1 fatigue / low energy
Anchor: the NAD+ route decision precedes a broad metabolic stack here.
Layer when: fatigue persists after food, fluids, sleep, electrolytes, and dose stability are settled.
Full guide: NAD+ Guide
Mitochondrial energy
Anchor: NAD+ + MOTS-c.
Layer when: post-viral fatigue, overtraining, aging stress, or GLP-1 fatigue remains stubborn.
Full guides: NAD+ and MOTS-c / Mito Stack
Injury recovery
Anchor: BPC-157 + TB-500 + NAD+ for most soft-tissue injuries.
Layer when: inflammatory cycling, poor collagen quality, nerve pain, sleep disruption, or the tissue type changes the problem.
Full guides: Wolverine Stack / Injury Recovery Protocol
Skin quality / GLOW / KLOW
Anchor: GLOW for calm skin; KLOW where inflammation is part of the skin problem.
Layer when: procedure recovery, reactive skin, hair shedding, or pigmentation goals call for an advanced layer.
Full guide: GLOW and KLOW
Gut / immune support
Anchor: routed by phenotype — post-viral depletion, immunosenescence, gut barrier, MCAS, or autoimmune pattern.
Layer when: immune stimulation fits the inflammation pattern once that pattern is understood.
Full guide: Immune Protocol
GH-axis support
Anchor: tesamorelin for visceral fat or lean-mass support; ipamorelin for cleaner pulse support.
Layer when: IGF-1 monitoring, glucose context, and growth-factor risks are acceptable.
Full guide: GH Secretagogue Comparison
Sleep / circadian disruption
Anchor: behavioral anchors first, then VIP, Selank, DSIP, Pinealon, or pineal support where indicated.
Layer when: sleep architecture still blocks recovery.
Full guide: Circadian Reset
Post-GLP-1 maintenance
Anchor: the taper-and-bridge window, before the drug fully washes out.
Layer when: appetite, lean mass, and energy expenditure call for replacement support.
Full guide: Semaglutide dosing calculator
What Makes a Stack Good?
A good stack has one anchor and one or more companions that solve different jobs.
Anchor Compound
The anchor creates the main effect.
- GLP-1s control appetite, glucose, and fuel routing.
- BPC-157 starts the soft-tissue repair signal.
- GLOW or KLOW anchors skin-quality work.
- NAD+ anchors active energy rebuild when fatigue is the main question.
- Tesamorelin anchors visceral-fat or lean-mass support.
The anchor should be readable before the stack grows. If the first compound has not been tested long enough to understand its effect, adding more makes the protocol harder to interpret.
Companion Compound
A companion solves the missing layer.
NAD+ belongs when the protocol increases energy demand: GLP-1 titration, injury repair, mitochondrial work, post-viral recovery, hard dieting, or post-GLP-1 maintenance.
MOTS-c belongs when the issue is fuel flexibility: training output, metabolic fatigue, GLP-1 drag, or poor fat-to-energy conversion.
SS-31 belongs when the mitochondrial membrane itself looks like the bottleneck: post-viral fatigue, overtraining, aging stress, or persistent energy fragility.
Tesamorelin or ipamorelin belongs when the issue is lean mass, visceral-fat phenotype, sleep-recovery pulse, or GH-axis support. Tesamorelin is the stronger visceral-fat and GLP-1 lean-mass tool. Ipamorelin is the cleaner modern GHRP-style pulse.
KPV belongs when inflammation keeps cycling. It is not a generic "more healing" peptide; it is an inflammation-control layer.
GHK-Cu belongs when skin, collagen, matrix quality, or tissue remodeling is the missing layer. In custom stacks it stays separate unless the product is a premixed GLOW/KLOW vial.
The Common Stack Families
GLP-1 Support Stacks
GLP-1s create the deficit. The support stack decides whether that deficit comes with energy, training output, and lean-mass preservation.
Fatigue first: NAD+ comes in ahead of a broad metabolic stack. IM is preferred for active support; oral NR or NMN still counts for maintenance.
Lean-mass or shape loss: GH-axis support enters here, usually tesamorelin when visceral fat, waist, or GLP-1 lean-mass protection is the problem. Ipamorelin can be a cleaner pulse companion when the stack calls for it.
Recomp or cut use: retatrutide or tirzepatide microdosing can be the actual destination for leaner users. Obesity-trial doses are the wrong target when the goal is food-noise control, waist reduction, and performance preservation.
Related: Retatrutide + NAD+ · Dual-Axis Recomp · GLP-1 Microdosing
Injury and Healing Stacks
The modern soft-tissue baseline is BPC-157 + TB-500 + NAD+. BPC-157 supports the blood-flow and repair-signal side. TB-500 supports repair-cell migration and tissue organization. NAD+ funds the energy cost of repair.
Escalation tracks the next bottleneck the injury shows:
- Inflammatory cycling: KPV.
- Poor collagen or tissue quality: GHK-Cu.
- Stalled energy / slow recovery: mitochondrial support.
- Nerve pain: ARA-290 or nerve-specific protocols.
- Sleep disruption: sleep itself, since repair is an overnight process.
Do not inject into tendons, joints, nerves, or deep structures at home. Near-injury SubQ can be useful when the area is easy and safe to reach; deep structures should route to normal SubQ or clinician care.
Related: Wolverine Stack · Injury Recovery Protocol · Where to Inject Peptides
Mitochondrial and Energy Stacks
Energy stacks are not just "longevity stacks." They are most useful when a real energy bottleneck exists: GLP-1 fatigue, post-viral depletion, overtraining, poor recovery, age-related energy decline, or a hard metabolic cut.
The clean starter version is NAD+ + MOTS-c. NAD+ supplies redox currency. MOTS-c sends the adaptation signal that improves fuel use and mitochondrial capacity.
SS-31 is the escalation layer. It fits when the issue looks structural: poor recovery despite NAD+ and MOTS-c, post-viral fatigue, persistent mitochondrial fragility, or overtraining stress.
Related: NAD+ and MOTS-c · Mito Stack
GLOW, KLOW, and Skin Stacks
GLOW and KLOW are already stacks.
- GLOW: GHK-Cu + BPC-157 + TB-4
- KLOW: GHK-Cu + BPC-157 + TB-4 + KPV
Standard skin-quality use can run on the cocktail alone. Advanced add-ons depend on the problem:
- Aging or damaged skin: NAD+ can support the energy demand of collagen remodeling.
- Reactive skin or rosacea pattern: KLOW is the better base; Selank and NAD+ can matter when stress and recovery are part of the flare pattern.
- Post-procedure recovery: KLOW fits better than GLOW when inflammation is the limiting layer.
- Hair shedding during GLP-1 use or hard cuts: the deficit is the first lever. Scalp-local support runs on topical GHK-Cu or AHK-Cu and minoxidil; GH peptides are not the default hair answer.
- Photoprotection / tanning: skin quality and a melanocortin strategy pair only carefully, since deeper pigment on irritated skin is the wrong trade.
Related: GLOW and KLOW · GLOW Calculator · KLOW Calculator
Gut and Immune Stacks
Immune support is not one stack. It depends on the failure pattern.
Post-viral depletion, immunosenescence, gut-barrier inflammation, mast-cell reactivity, and autoimmune flares are different problems. Pushing thymosin alpha-1 harder is not the right answer for every immune complaint.
The pattern routes the stack:
- Post-viral depletion: the target is T-cell and redox capacity.
- Aging immune decline: thymic output and NAD+/glutathione capacity.
- Gut or mucosal inflammation: barrier repair and calmer local inflammatory signaling.
- Mast-cell pattern: the trigger threshold stabilizes before immune stimulation.
- Active autoimmune flare: clinical evaluation comes first.
Related: Immune Peptide Protocol
GH and Sleep Stacks
GH peptides are not interchangeable.
Tesamorelin is the practical workhorse for visceral-fat phenotype, GLP-1 lean-mass support, and recomp stacks. Ipamorelin is the cleaner modern GHRP-style pulse for sleep and recovery support. Sermorelin is a gentler GHRH fallback. GHRP-2 and GHRP-6 are older and noisier for most users.
Timing matters: GH peptides usually belong in a bedtime low-insulin window, roughly 2+ hours after food and 60-90 minutes before sleep.
Sleep stacks are separate. If the bottleneck is circadian rhythm, anxiety, or slow-wave sleep, VIP, Selank, DSIP, Pinealon, or a pineal-restoration course may fit better than simply pushing GH harder.
Related: GH Secretagogue Comparison · Circadian Reset
How to Build a Stack Without Losing the Signal
1. The Anchor
The anchor is the compound that directly matches the goal. Three compounds at once, because a forum protocol looks impressive, is the failure mode here.
2. Route and Tolerability
Injection site, route, and BAC-water choice can make a stack look worse than it is. NAD+ usually fits IM better than SubQ. MOTS-c and SS-31 often benefit from NaCl BAC water. GHK-Cu can sting, but it is not a default NaCl compound.
Related: Where to Inject Peptides
3. Observation Before Adding
The anchor needs enough time to show its pattern. For weekly GLP-1s, that usually means several weeks at a stable dose. For injury stacks, it means pain, range of motion, load tolerance, swelling, and sleep watched over the first few weeks.
4. One Companion
The companion that enters is the one that solves the bottleneck. NAD+, MOTS-c, tesamorelin, KPV, and GHK-Cu all at once is reserved for a dedicated protocol that explicitly requires that architecture and a user who can monitor it.
5. Escalation After a Failure Pattern Appears
Escalation answers a specific sentence:
- "Energy is the bottleneck."
- "Inflammation keeps cycling."
- "Lean mass is slipping."
- "Sleep is blocking recovery."
- "The GLP-1 dose is stable but fatigue persists."
- "The injury improved, but collagen quality or load tolerance is not following."
A vague sentence is the signal to hold.
Timing Rules That Matter
GLP-1s: weekly injections stay separate, since titration and side effects need clean attribution.
GH peptides: bedtime or evening low-insulin window. Food and high insulin blunt the pulse logic.
MOTS-c and L-Carnitine: usually morning, fasted, or pre-training when the goal is oxidation and training output.
NAD+: IM is preferred for active support. Timing can be flexible, but many users tolerate it best away from bedtime.
BPC-157 / TB-500: injury-adjacent SubQ when practical and safe; normal SubQ when the injury is deep or awkward.
GLOW/KLOW: abdomen or thigh SubQ. These are premixed cosmetic/skin-quality cocktails, not local injury injections.
Mixing and Reconstitution Rules
Same goal does not mean same syringe.
Keep separate by default: GLP-1s, NAD+, SS-31, MOTS-c, L-Carnitine, glutathione, and GHK-Cu in custom stacks.
Premixed exception: GLOW and KLOW are already lyophilized together. Inject the premix as supplied. Do not use GLOW/KLOW as proof that any separate GHK-Cu/BPC/KPV/TB vials belong in one syringe.
Common simple pairing: BPC-157 + KPV is often reasonable in the same injection when the protocol is designed that way. TB-500/TB-4 may be added on TB days in some injury protocols.
BAC-water rule: standard BAC water is the default. NaCl BAC water is mainly for SS-31, MOTS-c, and recurring sermorelin/ipamorelin welts. NAD+ is best bought as a buffered version and reconstituted with NaCl BAC water. GHK-Cu can sting, but standard BAC remains the default unless the product says otherwise.
Related: Peptide Reconstitution Calculator · Peptide Calculator
Safety and Monitoring
The more signals a stack touches, the more monitoring matters.
Growth-factor context: GH-axis compounds, BPC-157, TB-500/TB-4, and GHK-Cu deserve caution in active malignancy or unresolved growth-factor risk contexts.
GLP-1 context: dehydration, constipation, appetite collapse, elevated resting heart rate, insomnia, or training collapse are the conditions a GLP-1 stack does not escalate through.
GH-axis monitoring: tesamorelin, ipamorelin combinations, sermorelin, MK-677, or hGH-style protocols should be tracked with IGF-1 and glucose context when used beyond casual short pulses.
Immune context: active autoimmune flare, mast-cell crisis, acute hyperinflammation, or infection-risk complexity should not be treated as a reason to blindly stimulate immunity.
Athlete context: several peptides are WADA-prohibited. Tested athletes need a separate decision process before using any performance-relevant compound.
FAQ
What is peptide stacking?
Peptide stacking means combining compounds that solve different bottlenecks in the same goal. A good stack is not a longer list. It is a cleaner sequence.
What is the best peptide stack?
There is no universal best stack. For soft-tissue injury, the starter answer is BPC-157 + TB-500 + NAD+. For cellular energy, NAD+ + MOTS-c is the clean starter and SS-31 is the escalation layer. For skin quality, GLOW or KLOW is already the stack. For GLP-1 users, the best companion depends on the problem: NAD+ for fatigue, GH-axis support for lean mass, or a post-GLP-1 bridge during taper.
How many peptides can you stack?
The common starting point is one anchor and one companion. Three or four compounds can make sense when each has a distinct job. Six-plus compound stacks are advanced and rest on a clear reason, a monitoring plan, and a stable prior response to each component.
What is the Wolverine Stack?
The modern soft-tissue Wolverine Stack combines BPC-157, TB-500, and NAD+. BPC-157 supports blood flow and repair signaling, TB-500 supports repair-cell movement and tissue organization, and NAD+ supplies the energy repair cells spend.
Can I stack GLP-1s with NAD+?
Yes. NAD+ is one of the most logical GLP-1 companions when fatigue, low training output, or hard-deficit stress appears. IM is preferred for active support; oral NR or NMN can still be useful for maintenance.
Should I use semaglutide, tirzepatide, or retatrutide in a stack?
For most weight-loss and body-composition users, tirzepatide is the cleaner default than semaglutide. Semaglutide still fits when GLP-1-only exposure, access, outcomes evidence, or prior tolerability matters. Retatrutide is more phenotype-sensitive: visceral-fat, liver-fat, recomp, plateau, or tirz-to-reta transition logic can make it compelling, but fast titration is the main failure mode.
Are GH peptides necessary for every stack?
No. GH peptides belong when the bottleneck is lean mass, visceral fat, sleep/recovery pulse, or GH-axis support. They are not a generic add-on for every injury, hair, or weight-loss protocol.
Do all stacked peptides go in the same syringe?
No. Same protocol does not mean same syringe. Keep GLP-1s, NAD+, SS-31, MOTS-c, L-Carnitine, glutathione, and custom GHK-Cu stacks separate unless a product is specifically manufactured as a premix.
Related Guides
- Wolverine Stack - soft-tissue injury baseline
- Injury Recovery Protocol - escalation by injury bottleneck
- NAD+ and MOTS-c - starter energy stack
- Mito Stack - SS-31 + MOTS-c + NAD+
- Retatrutide + NAD+ - GLP-1 support layer
- Dual-Axis Recomp - advanced recomp protocol
- GLOW and KLOW - skin-quality stacks
- Immune Peptide Protocol - immune routing by phenotype
- Circadian Reset - sleep and rhythm support
- GH Secretagogue Comparison - GH peptide choice
- Where to Inject Peptides - route and site decisions
- Reconstitution Calculator - BAC water, storage, and peptide prep
References
- Retatrutide obesity trial - triple GLP-1/GIP/glucagon receptor agonist dose-response in obesity. Jastreboff AM et al. NEJM 2023. DOI 10.1056/NEJMoa2301972
- Tirzepatide body-composition context - GLP-1/GIP agonism and weight-loss efficacy in SURMOUNT studies. Jastreboff AM et al. NEJM 2022. DOI 10.1056/NEJMoa2206038
- MOTS-c metabolic signaling - mitochondrial-derived peptide supports metabolic homeostasis and insulin sensitivity in preclinical models. Lee C et al. Cell Metabolism 2015. DOI 10.1016/j.cmet.2015.02.009
- SS-31 / elamipretide mitochondrial membrane mechanism - cardiolipin-protective peptide and mitochondrial energetics. Szeto HH. Br J Pharmacol 2014. DOI 10.1111/bph.12461
- BPC-157 review - brain-gut axis and stable gastric pentadecapeptide BPC-157 mechanisms. Sikiric P et al. Curr Neuropharmacol 2016. PMID 27640518
- Thymosin beta-4 / TB-4 applications - tissue repair and regenerative-medicine context for TB-4 biology. Goldstein AL, Kleinman HK. Expert Opin Biol Ther 2015. PMID 25586101
- GHK-Cu repair signaling - copper peptide effects on skin and tissue remodeling gene expression. Pickart L, Margolina A. Int J Mol Sci 2018. DOI 10.3390/ijms19071987
- KPV anti-inflammatory effects - alpha-MSH-related tripeptide KPV and inflammatory signaling. Luger TA et al. PNAS 2000. PMID 10639171
- VIP immune functions - vasoactive intestinal peptide as an immune-regulating neuropeptide. Delgado M, Ganea D. Amino Acids 2013. DOI 10.1007/s00726-011-1184-8
Educational only. Peptide stacks, off-label uses, and research peptides should be discussed with a qualified clinician, especially when combining metabolic, immune, GH-axis, or injury-repair signals.
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.